webinar

Informational Webinar

In this informational methods webinar, Dr. Scott Cribbes, Director of Applications and Emerging Markets at Nexcelom Bioscience will take a look at 3D models. It is a hot topic and he will explore why so many researchers are interested in working in 3D models. (Teaser: MCTS assays are more clinically relevant and predictive models than 2D assays) This presentation covers everything you need consider and evaluate if you’re considering working in 3D models. Dr. Cribbes reviews and explore the confusing terminology out there surrounding 3D models – multicellular tumor spheroids (MCTS); tumorspheres (TS); tissue-derived tumor spheres (TDST); organotypic multicellular spheroids (OMS) – how are these different? Similar? Dr. Cribbes move on to explain the MCTS model and the current methods to generate 3D spheroids. There’s discussion of considerations that need to be made prior to moving to a 3D model, to help ensure the greatest potential for success, and also examine ultra-low attachment u-bottom plates and discuss the significant advantages of using these when working with 3D MCTS. Finally, he’ll review a few assays popular for MCTS including: drug effect assays (growth inhibition, viability and apoptosis screens). Lastly, Dr. Cribbes also speaks about the Celigo image cytometer as a solution for imaging and analysis of 3D MCTS kinetic and endpoint assays.